Cargando…
Antibody recognition of the tumor-specific bcr-abl joining region in chronic myeloid leukemia
Chronic myeloid leukemia (CML) is characterized by the presence of a 210-kD protein (P210bcr-abl) in the cytoplasm of leukemic cells, generated by the reciprocal translocation between chromosome 9 and chromosome 22. Due to this translocation, the abl oncogene is coupled to the bcr gene, forming a ne...
Formato: | Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Rockefeller University Press
1989
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2189189/ https://www.ncbi.nlm.nih.gov/pubmed/2462613 |
Ejemplares similares
-
Pharmacogenetics of BCR/ABL Inhibitors in Chronic Myeloid Leukemia
por: Polillo, Marialuisa, et al.
Publicado: (2015) -
BCR-ABL Promotes PTEN Downregulation in Chronic Myeloid Leukemia
por: Panuzzo, Cristina, et al.
Publicado: (2014) -
BCR-ABL Independent Mechanisms of Resistance in Chronic Myeloid Leukemia
por: Loscocco, Federica, et al.
Publicado: (2019) -
Heterogeneity of BCR-ABL rearrangement in patients with chronic myeloid leukemia in Pakistan
por: Tabassum, Najia, et al.
Publicado: (2014) -
Characteristics of BCR–ABL gene variants in patients of chronic myeloid leukemia
por: Amin, Huma, et al.
Publicado: (2021)